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Abstract
Introduction
Follow-up among women who have had an abnormal
Papanicolaou (Pap) smear is often poor in public hospitals
that serve women at increased risk for cervical cancer.
This randomized controlled trial evaluated and compared
the total cost and cost per follow-up of a tailored outreach
intervention plus usual care with the total cost and cost
per follow-up of usual care alone.
Methods
Women with an abnormal Pap smear (n = 348) receiv-
ing care at Alameda County Medical Center (Alameda
County, California) were randomized to intervention or
usual care. The intervention used trained community
health advisors to complement the clinic’s protocol for
usual care. We assessed the costs of the intervention and
the cost per follow-up within 6 months of the abnormal
Pap smear test result.
Results
The intervention increased the rate of 6-month follow-up
by 29 percentage points, and the incremental cost per fol-
low-up was $959 (2005 dollars). The cost per follow-up var-
ied by the severity of the abnormality. The cost per follow-
up for the most severe abnormality (high-grade squamous
intraepithelial lesion) was $681, while the cost per follow-
up for less severe abnormalities was higher.
Conclusion
In a health care system in which many women fail to get
follow-up care for an abnormal Pap smear, outreach work-
ers were more effective than usual care (mail or telephone
reminders) at increasing follow-up rates. The results sug-
gest that outreach workers should manage their effort
based on the degree of abnormality; most effort should be
placed on women with the most severe abnormality (high-
grade squamous intraepithelial lesion).
Introduction
The U.S. Preventive Services Task Force strongly rec-
ommends screening for cervical cancer using the
Papanicolaou (Pap) test in sexually active women aged 65
years or younger (1). Cost-effectiveness calculations for
cervical cancer screening are sensitive to the periodicity
with which women are screened and the prevalence or like-
lihood of cervical cancer in the population (2-4). Many
health care organizations recommend screening every two
or three years, unless the woman is at increased risk.
Efforts to find and to screen high-risk populations are fre-
quently more cost-effective than general population-based
screening strategies. A recent study showed that it is more
cost-effective to focus on women who are rarely or never
screened rather than on women who have had a prior nor-
mal Pap smear (5).
Even when women get screened, follow-up is not perfect.
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Published cost-effectiveness models frequently make
assumptions about the rate of follow-up; for instance,
Goldie et al assumed a 15% loss to follow-up with each
visit (6,7). Unfortunately, loss to follow-up can be much
higher in some populations. Past studies have shown that
up to 64% of low-income and ethnically diverse women fail
to get adequate follow-up after an abnormal Pap smear (8-
12). Although there is evidence that reminder and educa-
tional interventions are efficacious at improving recom-
mended follow-up compared with usual care (13,14), one
study indicates that these interventions are less success-
ful for low-income, ethnically diverse women (10).
Therefore, when health care providers screen low-income
or ethnically diverse women for cervical cancer and the
test result is abnormal, additional efforts to increase fol-
low-up may be warranted.
This randomized controlled trial evaluated and compared
the cost and cost per follow-up of a tailored outreach inter-
vention plus usual care with the cost and cost per follow-up
of usual care alone. Community health advisors (CHAs)
provided the tailored outreach through telephone and in-
person contact. In this study, we focused on women with an
abnormal Pap smear at a county hospital that serves a low-
income, racially and ethnically diverse population.
Methods
This study used outreach and tailored individual coun-
seling to improve follow-up among high-risk, public hospi-
tal patients with an abnormal Pap smear. We report on the
efficacy of the study and details of the intervention else-
where (15). Institutional review boards at the Northern
California Cancer Center, University of California at San
Francisco, and the Alameda County Medical Center
approved the study protocol.
The intervention was conducted at Alameda County
Medical Center (ACMC), which is the acute care public hos-
pital in Alameda County, California. Alameda is an urban,
industrialized county on the east side of the San Francisco
Bay Area. The county has a population of approximately
1.44 million residents, with a large concentration in the city
of Oakland. Fifty-nine percent of the county population is
nonwhite (16). ACMC has ambulatory care programs and
an emergency department that together provide outpatient
care to more than 120,000 women annually, many of whom
are low income. Of the 4139 medical–surgical hospitals in
the United States, ACMC ranked 38th in 2004 (first per-
centile) in its provision of care to Supplemental Security
Income (SSI) and Medicaid beneficiaries through the
Medicaid Disproportionate Share Hospital program, which
makes payments to hospitals that serve disproportionate
numbers of low-income patients with special needs (17).
Sample
Women with an abnormal Pap smear recorded in
ACMC’s laboratory database from September 1, 1999, to
August 31, 2001, were eligible to participate in the study.
The database was reviewed weekly during the study to
identify eligible women. An abnormal Pap smear included
atypical squamous cells of undetermined significance
(ASCUS), atypical glandular cells of undetermined signifi-
cance (AGUS), low-grade squamous intraepithelial lesion
(LGSIL), and high-grade squamous intraepithelial lesion
(HGSIL), according to the Bethesda system (18).
Women were excluded if they were aged 18 or younger or
older than 74, did not speak any English or Spanish, lived
outside of Alameda County, were in the process of follow-
ing up their abnormal Pap smear, or were pregnant with
an estimated date of delivery later than October 31, 2001
(which would have required outreach after the interven-
tion period). We randomized all eligible women. Because
the study was viewed as a quality improvement initiative,
consent was not required, and the introduction of selection
bias at the point of randomization was thus eliminated.
Randomization was stratified by degree of abnormality
(ASCUS, AGUS, LGSIL, and HGSIL) to balance the inter-
vention and control group. Analyses were based on inten-
tion to treat.
The main outcome was timely follow-up of the abnormal
Pap smear. In most cases, this was operationalized as the
initiation of follow-up within 6 months of the date of the
original abnormal Pap smear. Unless the abnormal result
was HGSIL, pregnant women or women who became preg-
nant before the 6-month follow-up were encouraged to seek
follow-up care shortly after delivery. Therefore, timely fol-
low-up for pregnant women was defined as initiation with-
in 3 months after the expected due date.
A total of 515 women with an abnormal Pap test were
identified; of these, 348 women were eligible. We random-
ized 178 women to the intervention group and 170 to the
usual care group.
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The intervention took place from January 2000 through
January 2001. The three CHAs were women; two were
African American and one was Latina and bilingual in
English and Spanish. All three had prior community
health outreach experience. The CHAs were trained on the
study protocol, were monitored by a research coordinator,
and were aided by a computerized participant tracking
system. The content of the intervention was developed
from formative research and closely matched constructs
from the Health Belief Model (19) and Social Cognitive
Theory (20).
The CHAs were housed in an office at ACMC. This loca-
tion gave them access to hospital databases and placed
them in close proximity to the clinics. The CHAs contact-
ed participants in the intervention group by telephone to
administer a brief demographic questionnaire. Following
the initial telephone contact, CHAs met with each
woman, administered a structured baseline question-
naire, and using an algorithm based on responses to the
survey, provided tailored education, counseling, and
referrals. The primary objective of the CHAs throughout
the intervention was to help the women achieve timely
follow-up of an abnormal Pap smear. This assistance typ-
ically included reminder telephone calls and help with
scheduling appointments. CHAs used hospital records to
ascertain whether appointments were kept, missed, can-
celled, or rescheduled, and they confirmed this informa-
tion by contacting the participants. If follow-up was not
obtained, the CHAs helped schedule another appoint-
ment and investigated whether there were any further
barriers to care. More details of the intervention are
reported elsewhere (15).
Usual care
ACMC provided all study participants with usual care
that included notification by telephone or mail. The type of
follow-up protocol by the clinic nurse or designee depended
on the degree of Pap smear abnormality. Women with the
most severe abnormality (HGSIL) were advised to have a
colposcopy within 2 weeks of the receipt of the test result.
Women with AGUS or LGSIL were advised to have a col-
poscopy within 6 to 8 weeks of the receipt of the test result.
Finally, women with ASCUS were advised to have anoth-
er Pap smear, followed by a colposcopy, depending on the
second test result.
Rescue
Women in the usual care group who did not have a fol-
low-up appointment after 6 months were assigned to the
CHAs for rescue. Women assigned to rescue were treated
the same as women in the intervention group. We tracked
the time spent on rescue by CHAs and excluded these costs
from the cost-effectiveness analysis.
Cost data
The CHAs helped develop forms to document each time
they talked to a participant or took action on her behalf.
The forms tracked time and incidental costs associated
with each participant and provided detailed information
on the incremental time spent with each participant. (The
client contact form used during the intervention is avail-
able in the Appendix.) We then computed a cost estimate
for the time spent on direct participant contact by using an
hourly wage with benefits ($22.28) based on administra-
tive records.
We recorded 426 hours of intervention time (direct par-
ticipant contact) or approximately 2.4 hours per woman
in the intervention group. Study payroll records indicat-
ed that the CHAs were paid for 1148 hours. After sub-
tracting the 426 hours, we assumed that the remaining
722 (63%) hours were spent performing intervention-
related work that did not include direct participant con-
tact, such as participation in training and meetings. Our
expectation had been, however, that CHAs would spend
10% to 15% of their time on intervention-related work.
Upon further investigation, the CHAs reported providing
help on other projects and studies during slow times. We
concluded that the 722 hours included these other proj-
ects and studies. The data did not allow us to identify
how much time, if any, should be excluded. Therefore, we
took a conservative approach and included all 722 hours
in the primary analysis.
In addition to the CHAs, the intervention employed a
supervisor who met weekly with the CHAs. This person
provided training and quality assurance for the CHAs; for
example, the supervisor reviewed CHA forms for com-
pleteness and accuracy. We calculated a total cost for qual-
ity assurance ($35 per hour with benefits) and then dis-
tributed this cost uniformly to each study participant.
Finally, we tracked office space and supply costs.
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Usual care was either a telephone call or a letter; the
choice depended on the degree of Pap smear abnormality.
We estimated the cost of a telephone call at $3 (labor) and
the cost of a letter at $1 (postage and labor). We estimated
patient travel costs by using straight-line distance between
the patient’s ZIP code and ACMC (21). Patient travel costs
reflected a combination of travel expenses and travel time.
We estimated travel expenses at $0.365 per mile based on
federal mileage reimbursement rates (22). We estimated
the cost of travel time by assuming 1.5 minutes per mile
and $19.04 per hour based on the Bureau of Labor
Statistics average blue-collar wage rate for the San
Francisco and Oakland areas (23). Travel costs were
incurred only for women who had follow-up. All costs were
standardized to 2005 dollars using the Bureau of Labor
Statistics Price Index for all urban consumers (23). We
assessed the association between the number of hours
CHAs spent with participants and number of contacts
using Pearson’s correlation coefficient.
Cost per follow-up
We calculated the incremental cost per follow-up by
using a societal perspective. We included all costs regard-
less of who incurred the costs during the study (24). In a
secondary analysis, we calculated the incremental cost per
follow-up by using a payer perspective. We determined the
cost of adding the intervention to usual care assuming only
the costs that the payer would bear. Extending the analy-
sis to include lifetime costs and benefits was beyond the
scope of the study.
The unit cost of the follow-up visit ($195) was calculated
as the weighted average of Medicare’s payment for col-
poscopy current procedure terminology (CPT) codes. The
ambulatory payment classification (APC) facility payment
was included. Colposcopy CPT codes have similar reim-
bursement rates, with the exception of colposcopy with
loop electrode biopsy. Calculating a weighted average cor-
rects for this exception because electrode biopsy is a rare
procedure. We used 2004 data from the Department of
Veterans Affairs to identify the frequency with which these
CPT codes were used (25).
Bootstrapping with 1000 replications enabled us to cal-
culate 95% confidence intervals (CIs) for the incremental
cost-effectiveness ratio (26). Bootstrapping also enabled us
to calculate nonparametric CIs without making assump-
tions about data distributions.
We ran two sensitivity analyses to identify whether the
results held when input parameters were changed.
Because wages in the San Francisco Bay Area are sub-
stantially higher than in other urban areas of the United
States, we employed a sensitivity analysis using the
national average for a customer service representative
(27). Second, we assumed that the 426 hours of CHA time
represented 85% of their time and the remaining 15% was
spent in meetings or in training; this assumption was con-
sistent with a recent mammography study (28).
Results
Sample characteristics
The intervention and control groups were not statistical-
ly different in terms of race and ethnicity, primary lan-
guage, age, pregnancy status, reason for Pap smear, sever-
ity of Pap smear abnormality, insurance status, or distance
from home to ACMC (Table 1). Approximately half of the
sample was African American and between the ages of 18
and 29 years. The majority was not pregnant (83%) and
received an abnormal screening on a routine Pap smear
(61%). Overall, 20% of the participants had either LGSIL
or HGSIL. All of the participants lived within 40 miles of
ACMC, except for four participants, all of whom were in
the control group. The mean travel distance was 7 miles for
the intervention group and 11 miles for the control group,
but the median distance was similar (5 miles, intervention;
4 miles, control).
Cost per woman
CHAs spent an average of 2.39 hours per intervention
group participant. After reconciling these data with the
administrative records, which allowed us to include indi-
rect time, the mean time spent per woman was 6.38 hours,
or approximately $155 (Table 2). The remaining interven-
tion-related costs included CHA quality assurance ($21 per
intervention participant) and office space and supplies
($31 per intervention participant). The average cost of
patient travel was $20 for women in the intervention
group. The follow-up visit cost $195 for those who had a fol-
low-up visit. In sum, the cost of the intervention averaged
$355 per woman from the societal perspective. The cost of
usual care averaged $1. Table 2 also shows that from the
payer perspective, the intervention cost $335 for the inter-
vention group and $67 for the control group.
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The incremental cost per follow-up was $959 (95% CI,
$787–$1367) from the societal perspective and $926 (95%
CI, $754–$1333) from the payer perspective (Table 3).
We calculated the cost per follow-up for women with
ASCUS/AGUS, LGSIL, and HGSIL. As shown in Table 3,
the costs did not vary much among these three groups, but
the effectiveness did. In fact, the intervention improved fol-
low-up for women with the most severe abnormality
(HGSIL). There were 15 such women in the intervention
group and 14 in the control group. After the intervention,
of the women with HGSIL, 87% of those in the interven-
tion group and 43% of those in the control group had docu-
mented follow-up.
The sensitivity analysis showed that the results were
relatively robust to the wage rate. In areas where CHAs
would be paid $17 per hour (compared to $22 in this study),
the cost per follow-up would be reduced from $959 to $836.
The results were more sensitive to assumptions about the
time CHAs spent in meetings or in training (indirect costs).
If we assumed that CHAs spent 85% of their time provid-
ing services, then the average time a CHA spent with a
woman would be 2.8 hours (instead of 6.38 hours), and cost
per follow-up would decrease from $959 to $660.
Staffing
For each woman in the intervention, the average costs
were the following: CHA time, $155; quality assurance,
$21; office space and supplies, $31. The total cost of the
intervention for each woman was $207 and for all 178
women, $36,846. The Figure shows data on the total
number of hours spent with participants, the total num-
ber of contacts made, and the total number of HGSIL con-
tacts made by the three CHAs each month. The Figure
illustrates the close relationship between the total num-
ber of contacts and total number of hours (Pearson r =
0.54; P < .001). Also evident is the wide variability in
workload over time.
Discussion
The CHAs were effective at increasing follow-up among
low-income, racially and ethnically diverse women who
have had an abnormal Pap smear. The incremental cost
per follow-up was $959 (2005 dollars). The total cost for the
outreach program for 178 women, including patient time
and follow-up care, was $50,132 more than usual care.
Although this program would cost less in other parts of the
country where labor is less expensive than in the Bay Area,
some health care providers may not be able to afford the
program. An alternative would be for a health care
provider to use usual care for women with ASCUS and
AGUS and to use CHAs for LGSIL, HGSIL, or both. The
cost per follow-up was lower (more favorable) for women
with HGSIL than for all other women. Targeting the pro-
gram on more severe abnormalities may make sense
because women with more severe abnormalities face the
greatest risk of cancer and have the most to gain from
obtaining follow-up.
In this study, 38% of the women receiving usual care had
follow-up within 6 months after the Pap smear. Because
we conducted the study in only one health care institution,
we can only speculate on why usual care was less effective
than what is often reported in the literature (10,29). In
fact, the study site is unique, which may explain the suc-
cess of the intervention as well as the poor response to
usual care. ACMC is a county facility treating a high pro-
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portion of uninsured women who face barriers to care and
have low health literacy. Many patients at ACMC have
limited financial resources and face cultural or language
barriers or both. Some have substance-use problems and
practice unsafe sexual behaviors and are at higher risk for
human papillomavirus and human immunodeficiency
virus. The outreach workers were trained to help the
women overcome many of the barriers they face. But until
more research is conducted in other settings, it is not
known whether this program could be transferable to
other county hospitals, public health systems, or managed
care programs.
We found that CHAs were successful at increasing rates
of follow-up in a health care system that uses convention-
al cytology. Recent clinical trials suggest that the conven-
tional management of cervical cancer screening creates
barriers because multiple visits are needed to screen, con-
duct follow-up, and treat. Single-visit screen-and-treat
approaches were more effective than usual care (30,31). In
populations in which many barriers inhibit adequate fol-
low-up, screen-and-treat approaches were also cost effec-
tive compared with usual care (7). However, these proto-
cols do not appear to change the long-term screening
behaviors of most women. Brewster et al found no differ-
ences between intervention and control groups in obtain-
ing a Pap smear a year later except for women with
HGSIL/AGUS (31). Even for women with HGSIL/AGUS in
the intervention group, only 63% had a Pap smear a year
later; this percentage leaves room for improvement (31).
Consequently, health care systems that adopt screen-and-
treat protocols may find value in combining screen-and-
treat protocols with educational interventions, such as the
use of CHAs.
The primary limitation of this study is that the incre-
mental cost per follow-up is an intermediate outcome and
assumes that greater rates of follow-up lead to improved
survival and quality of life. Most cost-effectiveness analy-
ses, however, use quality-adjusted life-years (QALYs) for
measuring effectiveness (24). Modeling the incremental
cost per QALY was beyond the scope of this study.
A second limitation of this study is the larger than
expected difference between the time recorded on the CHA
logs and the time reported in the CHA payroll records.
These two time estimates were not expected to match per-
fectly because the CHA logs only record time spent on
direct contact with participants. The CHA logs do not
record time spent in meetings or in training. We expected
the administrative records to show that 10% to 15% of the
CHAs’ time was spent on meetings and training, but we
found that 63% of their time was spent on activities that
did not involve direct contact with participants. This infor-
mation suggests that our cost findings are probably high.
It also highlights the fact that CHA workload is not uni-
formly distributed over time (Figure). Health care systems
that adopt this type of intervention should pay particular
attention to the volume of abnormal Pap smears. Health
care systems with electronic databases of laboratory
results can identify the number of abnormal Pap smears
over time. They can then make an informed decision about
the number of full-time equivalent staff needed to meet the
workload and how they manage variations in workload.
Health care systems could also look into other ways of pay-
ing CHAs. However, alternative payment methods could
affect incentive structures for CHAs, which could, in turn,
affect follow-up rates.
In summary, the use of CHAs to promote follow-up after
an abnormal Pap smear is both more costly and more effec-
tive than usual care. The incremental cost per follow-up
was $959 (2005 dollars), and this amount would likely be
smaller in other areas of the country where labor costs are
less than they are in the Bay Area. These findings are par-
ticularly relevant for public health care systems where
low-income and racially and ethnically diverse women
seek care.
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Race
African American 49.4 49.4 .31
Latina 37.1 32.9
White 6.7 5.3
Other 6.7 12.4
English speaking 65.7 68.2 .62
Age, y
18-29 46.6 50.0 .63
30-39 21.9 24.7
40-49 18.5 14.1
50-74 12.9 11.2
Pregnant 17.4 15.9 .70
Reason for Pap test
Routine 64.0 58.2 .53
Diagnostic 33.7 39.4
Unknown 2.2 2.4
Result of Pap test
ASCUS/AGUS 79.2 80.0 .98
LGSIL 12.4 11.8
HGSIL 8.4 8.2
Insurance status
Private 0.6 0 .71
Public non-HMO 13.5 11.8
Public HMO 16.3 19.4
Uninsured 59 55.9
Unknown 10.7 12.9
Distance from   7.0 (8.8) 11.3 (47.5) .24
home to hospital,  
mean miles (SD)
Tables
Table 1. Sample Characteristics of Intervention Group (Community Health Advisors Plus Usual Care) and Control Group (Usual
Care), Alameda County, California, 2000–2002
Pap indicates Papanicolaou; ASCUS, atypical squamous cells of undetermined significance; AGUS, atypical glandular cells of undetermined significance;
LGSIL, low-grade squamous intraepithelial lesion; HGSIL, high-grade squamous intraepithelial lesion; HMO, health maintenance organization. 
aP value for categorical variables was determined using Pearson’s chi-square test, and for continuous variables, t test.
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Intervention Group, % Control Group, %
Characteristic (n = 178) (n = 170) P Valuea
Intervention Group, % Control Group, %
Characteristic (n = 178) (n = 170) P ValueaTable 2. Comparison of Average Payer and Societal Costs per Woman (U.S. Dollars in 2005) in Intervention Group
(Community Health Advisors Plus Usual Care) and in Control Group (Usual Care), Alameda County, California, 2000–2002a
Payer costs
Outreach worker costs 155 (115) 0 (0)
Travel costs at .365 per mile 4 (7) 0 (0)
Office space and supplies 31 (0) 0 (0)
Outreach worker quality assurance 21 (0) 0 (0)
Usual care 1 (1) 1 (1)
Follow-up visit 123 (99) 65 (95)
Patient travel costs for follow-up visit 20 (21) 11 (20)
Total average unit cost from societal perspectiveb 355 (182) 77 (111)
Total average unit cost from payer perspectivec 335 (169) 67 (95)
aA standard deviation of 0 indicates a fixed cost.
bSocietal perspective includes all costs regardless of who would bear them.
cPayer perspective includes only the costs that the payer would bear.
Table 3. Incremental Societal and Payer Costs (U.S. Dollars in 2005) per Follow-up for Intervention Group (CHA Plus Usual
Care) and Control Group (Usual Care), Alameda County, California
Societal perspectivea
Control 77 — 0.32 — —
Intervention 355 278 0.61 0.29 959 (787-1367)
Payer perspectiveb
Control 67 — 0.32 —
Intervention 335 268 0.61 0.29 926 (754-1333)
Societal perspective by result of Pap test
ASCUS/AGUS
Control 75 — 0.32 — —
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Intervention Group Usual Care
Mean (SD) Mean (SD)
Cost (n = 178) (n = 170)
Incremental  Rate of 6-Month  Increase in Rate of Incremental Cost 
Perspective Cost, $ Cost, $ Follow Up 6-Month Follow Up for Follow-Up, $ (95% CI)
CI indicates confidence interval; Pap, Papanicolaou; ASCUS, atypical squamous cells of undetermined significance; AGUS, atypical glandular cells of undeter-
mined significance; LGSIL, low-grade squamous intraepithelial lesion; HGSIL, high-grade squamous intraepithelial lesion.
aSocietal perspective includes all costs regardless who would bear them.
bPayer perspective includes only the costs that the payer would bear.
(Continued on next page)VOLUME 4: NO. 1
JANUARY 2007
Societal perspective by result of Pap test (continued)
ASCUS/AGUS (continued)
Intervention 347 272 0.57 0.25 1090 (813-1658)
LGSIL
Control 74 — 0.30 — —
Intervention 374 300 0.64 0.34 882 (579-4584)
HGSIL
Control 105 — 0.43 — —
Intervention 405 300 0.87 0.44 681 (486-1989)
CI indicates confidence interval; Pap, Papanicolaou; ASCUS, atypical squamous cells of undetermined significance; AGUS, atypical glandular cells of undeter-
mined significance; LGSIL, low-grade squamous intraepithelial lesion; HGSIL, high-grade squamous intraepithelial lesion.
aSocietal perspective includes all costs regardless who would bear them.
bPayer perspective includes only the costs that the payer would bear.
Appendix
The client contact form used in this study is available for download as a Microsoft Word document on the Preventing
Chornic Disease Web site.
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Table 3. (continued) Incremental Societal and Payer Costs (U.S. Dollars in 2005) per Follow-up for Intervention Group (CHA
Plus Usual Care) and Control Group (Usual Care), Alameda County, California
Incremental  Rate of 6-Month  Increase in Rate of Incremental Cost 
Perspective Cost, $ Cost, $ Follow Up 6-Month Follow Up for Follow-Up, $ (95% CI)